CN113840601A - 使用双特异性抗EGFR/c-Met抗体和第三代EGFR酪氨酸激酶抑制剂的组合疗法 - Google Patents

使用双特异性抗EGFR/c-Met抗体和第三代EGFR酪氨酸激酶抑制剂的组合疗法 Download PDF

Info

Publication number
CN113840601A
CN113840601A CN202080035662.6A CN202080035662A CN113840601A CN 113840601 A CN113840601 A CN 113840601A CN 202080035662 A CN202080035662 A CN 202080035662A CN 113840601 A CN113840601 A CN 113840601A
Authority
CN
China
Prior art keywords
egfr
seq
cancer
met
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080035662.6A
Other languages
English (en)
Chinese (zh)
Inventor
S·拉奎尔
M·洛伦齐
S·摩尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Priority claimed from PCT/IB2020/054594 external-priority patent/WO2020230091A1/fr
Publication of CN113840601A publication Critical patent/CN113840601A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080035662.6A 2019-05-14 2020-05-14 使用双特异性抗EGFR/c-Met抗体和第三代EGFR酪氨酸激酶抑制剂的组合疗法 Pending CN113840601A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962847605P 2019-05-14 2019-05-14
US62/847605 2019-05-14
PCT/IB2020/054594 WO2020230091A1 (fr) 2019-05-14 2020-05-14 Polythérapies avec des anticorps anti-egfr/c-met bispécifiques et des inhibiteurs de tyrosine kinase egfr de troisième génération

Publications (1)

Publication Number Publication Date
CN113840601A true CN113840601A (zh) 2021-12-24

Family

ID=78716450

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080035662.6A Pending CN113840601A (zh) 2019-05-14 2020-05-14 使用双特异性抗EGFR/c-Met抗体和第三代EGFR酪氨酸激酶抑制剂的组合疗法

Country Status (12)

Country Link
EP (1) EP3968985A4 (fr)
JP (2) JP2022531980A (fr)
KR (1) KR20220010731A (fr)
CN (1) CN113840601A (fr)
AU (1) AU2020275272A1 (fr)
BR (1) BR112021022828A2 (fr)
CA (1) CA3140360A1 (fr)
EA (1) EA202193117A1 (fr)
IL (1) IL287962A (fr)
MA (1) MA55978A (fr)
MX (1) MX2021013955A (fr)
SG (1) SG11202112412QA (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025060962A1 (fr) * 2023-09-21 2025-03-27 Beijing Neox Biotech Limited Anticorps multi-spécifiques et leurs utilisations
WO2025067492A1 (fr) * 2023-09-28 2025-04-03 上海翰森生物医药科技有限公司 Utilisation d'un anticorps bispécifique dans la préparation d'un médicament pour le traitement de cancers
WO2025140701A1 (fr) * 2023-12-29 2025-07-03 上海安领科生物医药有限公司 Anticorps monoclonal anti-egfr, anticorps bispécifique correspondant, composition pharmaceutique et utilisation associées

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117460714A (zh) * 2021-04-30 2024-01-26 希望之城 用于癌症治疗的pcna抑制剂和egfr抑制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102014913A (zh) * 2008-03-06 2011-04-13 健泰科生物技术公司 C-met和egfr拮抗剂的联合疗法
US20140141000A1 (en) * 2012-11-21 2014-05-22 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
CN107098975A (zh) * 2012-11-21 2017-08-29 詹森生物科技公司 结合egfr和c‑met iii型纤连蛋白域的分子
WO2018194356A1 (fr) * 2017-04-21 2018-10-25 Yuhan Corporation Sel d'un composé dérivé d'aminopyridine, forme cristalline de celui-ci, et son procédé de préparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
PT2560993T (pt) * 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
EP3929190B1 (fr) * 2014-10-13 2024-12-25 Yuhan Corporation Composés et compositions de modulation des activités de kinase mutant egfr
MX2021010265A (es) * 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102014913A (zh) * 2008-03-06 2011-04-13 健泰科生物技术公司 C-met和egfr拮抗剂的联合疗法
US20140141000A1 (en) * 2012-11-21 2014-05-22 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
CN107098975A (zh) * 2012-11-21 2017-08-29 詹森生物科技公司 结合egfr和c‑met iii型纤连蛋白域的分子
WO2018194356A1 (fr) * 2017-04-21 2018-10-25 Yuhan Corporation Sel d'un composé dérivé d'aminopyridine, forme cristalline de celui-ci, et son procédé de préparation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025060962A1 (fr) * 2023-09-21 2025-03-27 Beijing Neox Biotech Limited Anticorps multi-spécifiques et leurs utilisations
WO2025067492A1 (fr) * 2023-09-28 2025-04-03 上海翰森生物医药科技有限公司 Utilisation d'un anticorps bispécifique dans la préparation d'un médicament pour le traitement de cancers
WO2025140701A1 (fr) * 2023-12-29 2025-07-03 上海安领科生物医药有限公司 Anticorps monoclonal anti-egfr, anticorps bispécifique correspondant, composition pharmaceutique et utilisation associées

Also Published As

Publication number Publication date
IL287962A (en) 2022-01-01
BR112021022828A2 (pt) 2022-04-12
SG11202112412QA (en) 2021-12-30
JP2025118606A (ja) 2025-08-13
CA3140360A1 (fr) 2020-11-19
JP2022531980A (ja) 2022-07-12
MX2021013955A (es) 2022-03-11
EP3968985A4 (fr) 2023-07-26
EP3968985A1 (fr) 2022-03-23
MA55978A (fr) 2022-03-23
EA202193117A1 (ru) 2022-02-11
KR20220010731A (ko) 2022-01-26
AU2020275272A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
US12448455B2 (en) Combination therapies with bispecific anti-EGFR/c-met antibodies and third generation EGFR tyrosine kinase inhibitors
US12599606B2 (en) Therapies with 3rd generation EGFR tyrosine kinase inhibitors
JP7783182B2 (ja) ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療
JP2025118606A (ja) 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法
US20250257139A1 (en) Use of Amivantamab to Treat Colorectal Cancer
CA3228195A1 (en) Methods for treatment of non-small cell lung cancer (nsclc)
US20230250195A1 (en) Methods for Reducing Infusion-Related Reactions in Patients Treated with EGFR/Met Bispecific Antibodies
CN121843963A (zh) 用于包含双特异性抗EGFR/c-Met抗体的疗法的给药方案
KR20260066109A (ko) 비소세포 폐암을 치료하는 방법
HK40066269A (en) Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
EA053046B1 (ru) Комбинированные терапии с использованием биспецифических антител к egfr/c-met и 3-го поколения ингибиторов тирозинкиназы egfr
EA046908B1 (ru) Комбинированные терапии с использованием биспецифических антител к egfr/c-met и 3-го поколения ингибиторов тирозинкиназы egfr
HK40116078A (en) Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
HK40081424A (en) Treatment of patients having c-met exon 14 skipping mutations
WO2026038160A1 (fr) Procédés de réduction de réactions liées à la perfusion chez des patients traités avec des anticorps bispécifiques egfr/met
CN118679186A (zh) 用于减少使用egfr/met双特异性抗体治疗的患者的输注相关反应的方法
EA050376B1 (ru) ЛЕЧЕНИЕ ПАЦИЕНТОВ, ИМЕЮЩИХ МУТАЦИИ, ВЫЗЫВАЮЩИЕ ПРОПУСК ЭКЗОНА 14 В c-Met

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40066269

Country of ref document: HK